Disclosed are dicarboxylic acid derivatives of general formula (I), wherein 1,2,4-oxadiazole group, or enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts thereof. Such compounds of formula (I) include 1-{ 4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]benzyl} piperidine-4,4-dicarboxylic acid. Processes for preparing the compounds of formula (I) are also disclosed as well as their use for treating transplant rejection, tissue graft rejection, immune disorders, autoimmune disorders, inflammatory and chronic inflammatory conditions, asthma, pollinosis, psoriasis, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulo-nephritis, atherosclerosis, multi-organ failure, sepsis, pneumonia, optic neuritis, polymyalgia rheumatica, uveitis, vasculitis, osteoarthritis, respiratory distress syndrome, ischemia reperfusion injury, chronic obstructive pulmonary disease, infection associated with inflammation, viral inflammation, influenza, hepatitis, Guillian-Barre syndrome, chronic bronchitis, restenosis, granulomatous disease, sarcoidosis, leprosy, scleroderma, Alzheimers disease as well as disorders related to impaired vascular integrity, cancers, disregulated angiogenesis or excessive neoangiogenesis.
